Cargando…

Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis

Idiopathic granulomatous mastitis (IGM) is a rare inflammatory breast disease mimicking breast cancer. Limited research has been conducted on the application of serum biomarkers. This study aims to investigate the association of serum biomarkers with disease severity in patients with IGM. From Novem...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yi-Min, Lo, Chiao, Cheng, Chiao-Feng, Lu, Cheng-Hsun, Hsieh, Song-Chou, Li, Ko-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150275/
https://www.ncbi.nlm.nih.gov/pubmed/34066203
http://dx.doi.org/10.3390/jcm10102077
_version_ 1783698112947159040
author Huang, Yi-Min
Lo, Chiao
Cheng, Chiao-Feng
Lu, Cheng-Hsun
Hsieh, Song-Chou
Li, Ko-Jen
author_facet Huang, Yi-Min
Lo, Chiao
Cheng, Chiao-Feng
Lu, Cheng-Hsun
Hsieh, Song-Chou
Li, Ko-Jen
author_sort Huang, Yi-Min
collection PubMed
description Idiopathic granulomatous mastitis (IGM) is a rare inflammatory breast disease mimicking breast cancer. Limited research has been conducted on the application of serum biomarkers. This study aims to investigate the association of serum biomarkers with disease severity in patients with IGM. From November 2011 to March 2020, medical records of patients with IGM were reviewed. Serum cytokine levels were measured in patients and healthy controls between July 2018 and March 2020. A total of 41 patients with histologically proven IGM were found. Serum interleukin (IL)-6 level was significantly higher in patients with IGM (n = 11) than healthy controls (n = 7). Serum IL-6 and C-reactive protein (CRP) levels were significantly higher in patients with severe disease than mild and moderate disease. Serum IL-6 (Spearman’s ρ = 0.855; p < 0.001) and CRP (Spearman’s ρ = 0.838; p = 0.001) levels were associated with time to resolution. A higher serum CRP level was associated with a longer time to resolution (B = 0.322; p < 0.001) in multiple linear regression analysis. Serum IL-6 and CRP levels can be used as biomarkers for the evaluation of disease severity in IGM. IL-6 may play a crucial role in the immunopathology of IGM.
format Online
Article
Text
id pubmed-8150275
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81502752021-05-27 Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis Huang, Yi-Min Lo, Chiao Cheng, Chiao-Feng Lu, Cheng-Hsun Hsieh, Song-Chou Li, Ko-Jen J Clin Med Article Idiopathic granulomatous mastitis (IGM) is a rare inflammatory breast disease mimicking breast cancer. Limited research has been conducted on the application of serum biomarkers. This study aims to investigate the association of serum biomarkers with disease severity in patients with IGM. From November 2011 to March 2020, medical records of patients with IGM were reviewed. Serum cytokine levels were measured in patients and healthy controls between July 2018 and March 2020. A total of 41 patients with histologically proven IGM were found. Serum interleukin (IL)-6 level was significantly higher in patients with IGM (n = 11) than healthy controls (n = 7). Serum IL-6 and C-reactive protein (CRP) levels were significantly higher in patients with severe disease than mild and moderate disease. Serum IL-6 (Spearman’s ρ = 0.855; p < 0.001) and CRP (Spearman’s ρ = 0.838; p = 0.001) levels were associated with time to resolution. A higher serum CRP level was associated with a longer time to resolution (B = 0.322; p < 0.001) in multiple linear regression analysis. Serum IL-6 and CRP levels can be used as biomarkers for the evaluation of disease severity in IGM. IL-6 may play a crucial role in the immunopathology of IGM. MDPI 2021-05-12 /pmc/articles/PMC8150275/ /pubmed/34066203 http://dx.doi.org/10.3390/jcm10102077 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Huang, Yi-Min
Lo, Chiao
Cheng, Chiao-Feng
Lu, Cheng-Hsun
Hsieh, Song-Chou
Li, Ko-Jen
Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis
title Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis
title_full Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis
title_fullStr Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis
title_full_unstemmed Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis
title_short Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis
title_sort serum c-reactive protein and interleukin-6 levels as biomarkers for disease severity and clinical outcomes in patients with idiopathic granulomatous mastitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150275/
https://www.ncbi.nlm.nih.gov/pubmed/34066203
http://dx.doi.org/10.3390/jcm10102077
work_keys_str_mv AT huangyimin serumcreactiveproteinandinterleukin6levelsasbiomarkersfordiseaseseverityandclinicaloutcomesinpatientswithidiopathicgranulomatousmastitis
AT lochiao serumcreactiveproteinandinterleukin6levelsasbiomarkersfordiseaseseverityandclinicaloutcomesinpatientswithidiopathicgranulomatousmastitis
AT chengchiaofeng serumcreactiveproteinandinterleukin6levelsasbiomarkersfordiseaseseverityandclinicaloutcomesinpatientswithidiopathicgranulomatousmastitis
AT luchenghsun serumcreactiveproteinandinterleukin6levelsasbiomarkersfordiseaseseverityandclinicaloutcomesinpatientswithidiopathicgranulomatousmastitis
AT hsiehsongchou serumcreactiveproteinandinterleukin6levelsasbiomarkersfordiseaseseverityandclinicaloutcomesinpatientswithidiopathicgranulomatousmastitis
AT likojen serumcreactiveproteinandinterleukin6levelsasbiomarkersfordiseaseseverityandclinicaloutcomesinpatientswithidiopathicgranulomatousmastitis